Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Stoke Therapeutics (STOK – Research Report). The associated price target is $29.00.
Thomas Shrader’s Buy rating for Stoke Therapeutics is grounded in the anticipation of positive outcomes from the upcoming data on STK-001. He believes that the treatment will demonstrate a marked reduction in seizure frequency for Dravet syndrome patients who are already on maximum treatment regimens. Shrader’s confidence is further bolstered by the potential of STK-001 to address the non-seizure symptoms of the syndrome, which the recent natural history data suggests could be significant, even if it may take time to reverse long-standing impairments in these patients.
Additionally, Shrader’s optimism extends to Stoke’s pipeline, with STK-002 showing promise in treating blindness in patients with ADOA—a disease affecting mitochondrial function. He notes the advantage of targeting the eye for TANGO-based genetic modulation, where the delivery is safe and the treatments have long residence times. Preclinical data supporting the efficacy of STK-002 and its safety, even at elevated OPA1 levels, further support his positive outlook on Stoke Therapeutics. The company’s progress and expected milestones, such as dosing the first patient with STK-002 in 2023, contribute to Shrader’s Buy rating.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $35.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Stoke Therapeutics (STOK) Company Description:
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Read More on STOK:
